TMO · Thermo Fisher Scientific Inc.

Thermo Fisher Scientific delivered robust Q1 2026 financial results, with revenue reaching $11.0 billion, up 6.2% from $10.4 billion in the prior year quarter. This growth occurred amid a complex environment of segment-specific dynamics, including bioproduction momentum from higher pharma and biotech demand alongside the 2025 filtration and separation acquisition, which contributed meaningfully to Life Sciences performance on a reported basis. However, headwinds from tariffs, related foreign exchange impacts, unfavorable business mix, and lower volumes in areas like academic and government markets tempered the topline expansion. Productivity improvements provided critical offsets, enabling the company to navigate these pressures while advancing its proven growth strategy.

Profitability strengthened as operating income climbed 8.6% to $1.9 billion, achieving a 16.9% operating margin. The GAAP operating margin saw a slight decrease, primarily due to the factors impacting segments—tariffs, FX, mix shifts, and volume declines—but this was more than offset by significantly lower restructuring and other charges. These charges, tied to prior headcount reductions and facility consolidations aimed at streamlining operations, declined notably from the prior period (Note 6). Segment income margins reflected varied performance: certain areas experienced contractions from unfavorable mix, strategic investments, and FX headwinds, largely offset by very strong productivity; others benefited from productivity and favorable FX, despite unfavorable volume leverage. Net income rose 9.3% to $1.7 billion, and diluted EPS increased 11.3% to $4.43, underscoring effective cost management and operational execution.